Literature DB >> 35972581

RP11-79H23.3 Inhibits the Proliferation and Metastasis of Non-small-cell Lung Cancer Through Promoting miR-29c.

Mulin Liu1, Chang Liu1, Xi Li2, Shijun Li3.   

Abstract

Evidences indicate that long non-coding RNAs (lncRNAs) are closely involved and contributed to tumorigenesis and cancer progression. As a novel lncRNA, RP11-79H23.3 was found to be an anti-oncogene in bladder cancer. However, the essential roles and functions of RP11-79H23.3 in non-small-cell lung cancer (NSCLC) remains to be elucidated. Here, loss of functional assay was applied to gain insights into the functions of RP11-79H23.3 on the proliferation and metastasis capabilities of A549 and H1299 cells. Meantime, Real-time PCR was utilized to measure RP11-79H23.3 and miR-29c expression in NSCLC tissues. Dual-luciferase reporter assay, CCK8, colony formation assay, transwell and Western blot were performed to illustrate the potential molecular basis of RP11-79H23.3 in NSCLC. RP11-79H23.3 downregulation facilitated cell proliferation, migration, and invasion of NSCLC. The result of dual-luciferase reporter assay represented a direct interaction of RP11-79H23.3 with miR-29c, which suppressed miR-29c expression that showed inversely correlation in NSCLC. Moreover, RP11-79H23.3 siRNA facilitated the progression of NSCLC partially via regulating the expression of miR-29c and the activation of Wnt/β-catenin signaling pathway. Our findings highlighted that RP11-79H23.3, served as an anti-oncogene, accelerated NSCLC progression through sequestering miR-29c, providing a promising therapeutic target for NSCLC.
© 2022. The Author(s).

Entities:  

Keywords:  Metastasis; Non-small-cell lung cancer; Proliferation; RP11-79H23.3; miR-29c

Year:  2022        PMID: 35972581     DOI: 10.1007/s10528-022-10263-y

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   2.220


  29 in total

Review 1.  LncRNAs in human cancers: signal from noise.

Authors:  Sara Adnane; Alessandro Marino; Eleonora Leucci
Journal:  Trends Cell Biol       Date:  2022-02-12       Impact factor: 21.167

2.  MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.

Authors:  Mengqi Deng; Di Wu; Yanqin Zhang; Zhaoyu Jin; Jinwei Miao
Journal:  Gynecol Oncol       Date:  2021-04-17       Impact factor: 5.482

3.  Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression.

Authors:  Zhuoan Cheng; Chunlai Lu; Hui Wang; Ning Wang; Shaohua Cui; Chengtao Yu; Cun Wang; Qiaozhu Zuo; Siying Wang; Yuanyuan Lv; Ming Yao; Liyan Jiang; Wenxin Qin
Journal:  Cancer Lett       Date:  2022-01-29       Impact factor: 8.679

4.  LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.

Authors:  Ravindra Pramod Deshpande; Sambad Sharma; Yin Liu; Puspa Raj Pandey; Xinhong Pei; Kerui Wu; Shih-Ying Wu; Abhishek Tyagi; Dan Zhao; Yin-Yuan Mo; Kounosuke Watabe
Journal:  Breast Cancer Res       Date:  2022-01-25       Impact factor: 6.466

5.  LncRNA SNHG1 Promotes the Progression of Pancreatic Cancer by Regulating FGFR1 Expression via Competitively Binding to miR-497.

Authors:  Shihong Chen; Wenyi Guo; Mingyang Meng; Dong Wu; Tao Zhou; Lei Wang; Jianwei Xu
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

Review 6.  Role of Long Non-Coding RNA LINC00641 in Cancer.

Authors:  Xue Han; Shitai Zhang
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

7.  lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway.

Authors:  Qingkun Jiang; Zhonghao Wang; Qi Qi; Jialun Li; Yuqi Xin; Jiaxuan Qiu
Journal:  Mol Ther Oncolytics       Date:  2021-12-31       Impact factor: 7.200

8.  LncRNA TMPO-AS1 suppresses the maturation of miR-335-5p to participate in polycystic ovary syndrome.

Authors:  Fang Hou; Jie Li; Jie Peng; Zhenghua Teng; Jun Feng; Weiwei Xia
Journal:  J Ovarian Res       Date:  2021-07-30       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.